5-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine

Catalog No. :
ACMZEJ970
CAS No. :
2057507-40-9
Molecular Formula :
C13H22BN3O2
Molecular Weight :
263.15

IUPAC Name:5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine

5-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$353.00Login to see priceInquiryInquiry
100mg95%$519.00Login to see priceInquiryInquiry
250mg95%$734.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine
IUPAC Name5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine
Molecular FormulaC13H22BN3O2
Molecular Weight263.15
SMILESCC1(C)C(C)(C)OB(C2=C3CN(C)CCN3N=C2)O1
InChI KeyJWRCPHDXYJIWEI-UHFFFAOYSA-N
Synonym5-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine;5-methyl-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-4H,5H,6H,7H-pyrazolo[1,5-a]pyrazine
CAS No.2057507-40-9

Synthetic Route by SureRoute

1. ACMZEJ970 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMZEJ970 route product structure diagram
    ACMZEJ9702057507-40-9
Inquiry

2. ACMZEJ970 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMZEJ970 route product structure diagram
    ACMZEJ9702057507-40-9
Inquiry

Comments (0)